News

June 8, 2020

HistoSonics Announces $40 Million Financing

HistoSonics announced today that it has closed $40 million in an oversubscribed Series C-1 financing. The round was led by […]
January 13, 2020

HistoSonics Wins Top Honors in The Observer’s List of Top Healthcare Start-ups

HistoSonics was named by The Observer as one of the nation’s most influential healthcare companies during the 38th J.P. Morgan […]
January 13, 2020

HistoSonics Wins Top Honors in The Observer's List of Top Healthcare Start-ups Heading into the JP Morgan Healthcare Conference

HistoSonics, developer of a novel non-invasive sonic beam therapy platform, was named by The Observer as the one of the […]
January 6, 2020

HistoSonics Wins Prestigious Frost & Sullivan Award

Frost & Sullivan announced that it has awarded HistoSonics its prestigious 2019 North American Technology Innovation Award for the development […]
April 8, 2019

HistoSonics Closes $54 Million Series C Financing

HistoSonics announced today that it has closed a $54 million Series C financing. The round was led by Varian Medical […]
April 7, 2019

HistoSonics' tech attracts health care heavyweights

Ann Arbor-based HistoSonics Inc. plans to announce Monday that it has closed on a venture-capital funding round of $54 million […]

Last updated on April 28, 2025

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on April 30, 2025
X New Twitter Logo
© 2019-2025 HistoSonics®. All rights reserved.
HistoSonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.